Drawing for AFFILIN

USPTO serial 79155885

AFFILIN

Reviewed by CopyMark Law Group

Reg. 4838850Status 706Registered
Filing date
Status date
Registration date
Oct 27, 2015
Examiner
HUSSAIN, TASNEEM
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with AFFILIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miki Motohashi Iino

Miki Motohashi Iino Millen, White, Zelano & Branigan, P.C.2200 Clarendon Blvd., Ste 1400Arlington, VA 22201United States

Goods and services

ClassDescriptionStatusFirst use
001[Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]SECTION 71 - CANCELLED—
005[Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]SECTION 71 - CANCELLED—
042Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic productsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 2, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 2, 2026NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Feb 2, 202671AGREGISTERED-SEC.71 ACCEPTED—
Jan 26, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 14, 2025ES71TEAS SECTION 71 RECEIVED—
Oct 28, 2024REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
May 24, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 30, 2023INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Mar 9, 2023INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Mar 9, 2023INPCINVALIDATION PROCESSED—
Jan 17, 2023INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 17, 2022NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
May 17, 202271.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
May 10, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 26, 2021ES71TEAS SECTION 71 RECEIVED—
Oct 27, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 15, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 12, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 12, 2016FIMPFINAL DISPOSITION PROCESSED—
Jan 27, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 27, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 21, 2015GPNXNOTIFICATION PROCESSED BY IB—
Aug 11, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 11, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 5, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 5, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 22, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 8, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 7, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 6, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jul 6, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 6, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 6, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 24, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 24, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 17, 2015ALIEASSIGNED TO LIE—
Jun 10, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 27, 2014RFNTREFUSAL PROCESSED BY IB—
Dec 12, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 10, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 10, 2014RFRRREFUSAL PROCESSED BY MPU—
Dec 9, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 8, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 8, 2014DOCKASSIGNED TO EXAMINER—
Dec 8, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 4, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance